.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Dow
QuintilesIMS
Baxter
Deloitte
Fish and Richardson
McKinsey
Harvard Business School
Boehringer Ingelheim
Johnson and Johnson

Generated: September 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021226

« Back to Dashboard
NDA 021226 describes KALETRA, which is a drug marketed by Abbvie and is included in three NDAs. It is available from nine suppliers. There are nineteen patents protecting this drug and two Paragraph IV challenges. Additional details are available on the KALETRA profile page.

The generic ingredient in KALETRA is lopinavir; ritonavir. There are thirteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the lopinavir; ritonavir profile page.

Summary for NDA: 021226

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:8
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength133.3MG;33.3MG
Approval Date:Sep 15, 2000TE:RLD:No
Patent:► SubscribePatent Expiration:Dec 26, 2016Product Flag?Substance Flag?Delist Request?
Patent:► SubscribePatent Expiration:May 7, 2018Product Flag?Substance Flag?Delist Request?Y
Patent:► SubscribePatent Expiration:Aug 15, 2016Product Flag?Substance Flag?Delist Request?

Expired Orange Book Patents for NDA: 021226



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Queensland Health
Fuji
Colorcon
Express Scripts
Covington
Harvard Business School
Accenture
Cipla
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot